Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study - Concepedia

Concepedia

Publication | Open Access

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

DOI Full Paper Access

1K

Citations

19

References

2016

Year

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma Scott, Ahmad Halwani, Martin Gutierrez, Michael Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic,

Journal of Clinical Oncology

Abstract

Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.

References

	Year	Citations

Page 1